Tech Company Financing Transactions
Mammoth Biosciences Funding Round
On 1/31/2020, Mammoth Biosciences raised $45 million in Series B funding from Decheng Capital and Verily.
Transaction Overview
Company Name
Announced On
1/31/2020
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series B
Investors
Decheng Capital (Lead Investor)
Proceeds Purpose
The company also uses its platform to discover new proteins and, with the funding, hopes to push those into clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1000 Marina Blvd. 600
Brisbane, CA 94005
USA
Brisbane, CA 94005
USA
Phone
Undisclosed
Website
Email Address
Overview
Mammoth's vision is to provide a CRISPR-based platform on which an infinite number of tests can be built by both ourselves and our partners - democratizing access to an endless variety of tests for bio sensing in healthcare, as well as across industries such as agriculture, manufacturing, forensics, and more.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Trevor Martin
Chief Operating Officer
Ted Tisch
Chief Scientific Officer
Lucas Harrington
Chief Technical Officer
Janice Chen
Co-Founder
Jennifer Doudna
VP - Bus. Development
Vikram Joshi
VP - Bus. Development
Peter Nell
Browse more venture capital transactions:
Prev: 1/31/2020: LaborChart venture capital transaction
Next: 1/31/2020: Contxtful venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC transactions on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs